T-Therapeutics

T-Therapeutics Limited is a biopharmaceutical company focused on developing cancer immunotherapies by utilizing T cell receptor (TCR) technology. Founded in May 2022 and based in the United Kingdom, the company aims to enhance cancer treatment by harnessing the natural ability of T cells to identify and eliminate tumors. The company employs its proprietary OpTiMus® platform to create optimal TCR-based therapeutics. This innovative platform generates fully human TCRs with unique properties, providing a vast source of antigen-specific TCRs that are not found in the natural human repertoire. T-Therapeutics is dedicated to developing safe and effective treatments for various cancers and autoimmune diseases, leveraging expertise in mouse genome engineering, biopharmaceutical development, single cell genomics, machine learning, and structural biology. With £48 million raised in Series A funding, T-Therapeutics is positioned for growth and advancement in therapeutic development, led by a skilled team including CEO Theodora Harold and Chairman Dr. David Hung.